This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
NACC1 / Nucleus accumbens-associated protein 1 · IHC design guide
Design Immunohistochemistry for NACC1
Plan NACC1 paraffin-section IHC around the ubiquitous nuclear tissue pattern (HPA tissue IHC). This guide covers the catalog antibody’s 2–5 μg/ml IHC range (datasheet A08675-3) and scoring nuclear staining (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
NACC1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Nuclear tissue staining; cytoplasm is possible (HPA tissue IHC; UniProt) | |
| Staining pattern | Ubiquitous nuclear staining across tissue cell types (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A08675-3) | |
| Positive control | Adipose tissue+4 more · see all | |
| Negative control | None in HPA (detected in all 45 tissues); use no-primary + isotype controls |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation conditions consistent across sections (standard IHC practice; not target-specific) | |
| Caveat | Phosphorylation may alter cytoplasmic distribution (UniProt) | |
| Regulation | Upregulated after chemotherapy in ovarian carcinoma (UniProt) | |
| Isoform / epitope | No annotated isoforms; one full-length chain (UniProt) |
Section 1
Recommended NACC1 IHC & IF Protocols
The catalog antibody’s IHC-P protocol is accompanied by published NACC1 staining methods for urothelial carcinoma sections (PMC6210667) and mouse and human embryonic tissues (PMC3724875).
| Sample | Paraffin-embedded human bladder epithelial carcinoma tissue; fixative not specified (datasheet A08675-3) |
| Fixation | Image fixative and duration unreported (datasheet A08675-3); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A08675-3); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A08675-3) |
| Primary antibody | Rabbit anti-NACC1, 2-5 μg/ml (datasheet A08675-3) |
| Primary incubation | Overnight at 4 °C (datasheet A08675-3) |
| Detection | Streptavidin-biotin complex (SABC), DAB chromogen (datasheet A08675-3) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | NACC1-positive staining in adipocytes of adipose tissue (HPA tissue IHC: High). HPA tissue profile: Ubiquitous nuclear expression. No signal in the no-primary control. |
💡Decision noteStart with EDTA pH 8.0 heat retrieval (datasheet A08675-3); the embryonic tissue protocol used citrate-based pH 7.4 retrieval (PMC3724875).
Section 2
What Is the Expected NACC1 Staining Pattern?
NACC1 should appear chiefly in nuclei across many cell types in paraffin-section IHC: HPA reports ubiquitous nuclear expression with Enhanced tissue-IHC reliability and low RNA tissue specificity (HPA: tissue IHC). Cytoplasmic distribution can occur and depends on phosphorylation (UniProt Q96RE7: subcellular location). NACC1 has no transmembrane segment, so a membrane-only pattern is unexpected (UniProt Q96RE7: topology). Interpret staining within the cell type being scored.
| Clear nuclear chromogen in adipocytes, adrenal or epididymal glandular cells, respiratory epithelium, neurons, glia, or decidual cells. | This fits the principal compartment and the listed high-staining cells (HPA: ubiquitous nuclear expression; High in the listed cells). Compare like cell types within a section: an organ-level judgment can hide a convincing nuclear result in its relevant cells (standard IHC interpretation). |
| Strong membrane-only staining, or a predominantly cytoplasmic pattern with little nuclear signal. | Recheck specificity and localization before calling this NACC1: HPA’s tissue profile is nuclear, and UniProt lists no transmembrane segment (HPA: tissue IHC; UniProt Q96RE7: topology). Cytoplasm alone is not proof of artifact, because phosphorylation-dependent cytoplasmic distribution is reported (UniProt Q96RE7: subcellular location). |
| Signal appears mainly in a different cell population from the one being assessed, while expected nuclei remain unstained. | Check cell identity, assay controls, and possible cross-reactivity or endogenous chromogenic activity (standard IHC interpretation). Broad NACC1 expression means an unexpected cell is not automatically negative; HPA provides cell-specific high and low observations, with no negative tissue listed (HPA: tissue IHC). |
| Hazy chromogen covers nuclei, cytoplasm, and spaces between cells without crisp cellular boundaries. | Treat this as unresolved background until the detection controls are reviewed (standard chromogenic IHC interpretation). A diffuse deposit cannot establish NACC1 localization, even where HPA reports high staining; the expected tissue pattern remains chiefly nuclear (HPA: tissue IHC). |
| A listed high-staining cell population shows no detectable nuclear signal. | First verify that the relevant cells are present and that the run’s positive control worked (standard IHC practice). Absence in one section cannot establish biological absence: HPA calls these populations High and rates its tissue-IHC evidence Enhanced (HPA: tissue IHC). |
💡Expected NACC1 appearanceCall a convincing positive when identifiable cells show crisp, chiefly nuclear staining, including strong staining in an HPA-listed High population; isolated membrane staining or diffuse, cell-free chromogen is suspect (HPA: tissue IHC; UniProt Q96RE7: topology; standard IHC interpretation).
| Cell-specific reference pattern | HPA lists High staining in adipocytes; adrenal and epididymal glandular cells; bronchial and nasopharyngeal respiratory epithelium; caudate neurons; cortical glia; and placental decidual cells (HPA: tissue IHC). Match the scored cell population to its reference; low RNA tissue specificity does not make every cell equally intense (HPA: RNA specificity and tissue IHC). |
| Low-staining comparators | HPA lists Low staining in parathyroid and prostate glandular cells, liver cholangiocytes, cardiomyocytes, and smooth muscle cells, but supplies no negative tissue (HPA: tissue IHC). These are weaker comparators, not validated zero-signal controls; an absent or faint result in one cannot validate a failed positive run (standard IHC interpretation). |
| Compartment and phosphorylation | HPA describes a chiefly nuclear tissue pattern and nucleoplasmic ICC-IF localization, with additional cytosol and vesicles (HPA: tissue IHC; HPA: subcellular ICC-IF). UniProt reports phosphorylation-dependent cytoplasmic distribution and phosphoserines at residues 188 and 259 (UniProt Q96RE7: localization and modified residues). Neither source establishes a fixation effect or a required cytoplasmic IHC intensity. |
| Antibody evidence | Two listed rabbit polyclonal antibodies have Enhanced IHC validation and Supported ICC status; the listed mouse monoclonal has Supported IHC status (HPA: antibody validation). This strengthens confidence in the reported nuclear reference pattern, while an individual assay still needs appropriate run controls (standard IHC practice). Validation status does not certify every tissue or staining condition. |
| Tumor context | UniProt reports NACC1 overexpression in several carcinomas, including ovarian serous carcinomas, and an association between intense primary-tumor immunoreactivity and early recurrence (UniProt Q96RE7: tissue specificity). Tumor intensity therefore needs comparison with the relevant cells and validated scoring context; staining alone is not a stand-alone clinical prediction (standard IHC interpretation). |
| Situation | Likely cause | Next action |
|---|---|---|
| No signal in an HPA-listed High population. | The relevant cells may be absent from the section, or the staining run may have failed (HPA: High cell list; standard IHC practice). | Confirm cell identity and morphology, then review the concurrent positive control and the catalog antibody’s IHC-P instructions for the run (standard IHC practice). |
| Only broad cytoplasmic staining is visible. | Cytoplasmic NACC1 is possible, but a nuclear-poor result departs from HPA’s dominant tissue pattern (UniProt Q96RE7: localization; HPA: tissue IHC). | Check nuclear counterstain, cell boundaries, and control sections before scoring; record cytoplasmic signal separately from convincing nuclear staining (standard IHC interpretation). |
| Strong membrane outlines dominate the slide. | A membrane-only pattern is unsupported by the reported localization and absence of a transmembrane segment (HPA: tissue IHC; UniProt Q96RE7: topology). | Review primary-antibody omission and detection controls for nonspecific or endogenous signal; reassess specificity if outlines persist (standard chromogenic IHC practice). |
| Every area has diffuse brown background. | Unresolved chromogen may reflect nonspecific binding or endogenous detection activity (standard chromogenic IHC practice). | Inspect the no-primary control, blocking and washing steps, and detection chemistry; score only staining with interpretable cellular boundaries (standard IHC practice). |
| A Low comparator stains more strongly than expected. | HPA’s Low category is an observed level, not a promise of no staining; cell composition and background can complicate comparison (HPA: tissue IHC; standard IHC interpretation). | Identify the exact scored cells and compare their nuclear signal with a concurrent High population; inspect detection controls if staining lacks cellular definition (HPA: High and Low cell lists; standard IHC practice). |
| Q: What if IF/ICC shows cytosolic NACC1? | HPA supports nucleoplasm as the main ICC-IF location and cytosol as an additional location; UniProt links cytoplasmic distribution to phosphorylation (HPA: subcellular ICC-IF; UniProt Q96RE7: localization). | A: Interpret it alongside the nuclear signal and appropriate controls; cytosol alone does not define the expected paraffin-section IHC pattern (HPA: tissue IHC; standard IHC interpretation). |
Experiment evidence
IHC & IF images showing NACC1 staining
A08675-3 · IHCIHC analysis of Nac1/NACC1 using anti-Nac1/NACC1 antibody (A08675-3). Nac1/NACC1 was detected in a paraffin-embedded section of human bladde
A08675-3 · IHCIHC analysis of Nac1/NACC1 using anti-Nac1/NACC1 antibody (A08675-3). Nac1/NACC1 was detected in a paraffin-embedded section of human papill
A08675-3 · IFIF analysis of Nac1/NACC1 using anti-Nac1/NACC1 antibody (A08675-3). Nac1/NACC1 was detected in an immunocytochemical section of MCF-7 cells
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000160877-NACC1/tissue/cerebral+cortex#imid_19353879
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000160877-NACC1/tissue/colon#imid_19353805
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000160877-NACC1/tissue/liver#imid_19401601
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000160877-NACC1/tissue/kidney#imid_19353799
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA021238; green = NACC1, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA021238; green = NACC1, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for NACC1 IHC & IF
🧪Run adipose tissue first and score NACC1 staining in adipocytes (High; HPA: adipose tissue, adipocytes). HPA lists no negative tissue because NACC1 is detected in all 45 scored tissues (HPA: no negative rows); use no-primary and isotype controls for the negative comparison, and treat unstained cells on the positive slide as an internal negative only if their identity and lack of NACC1 are independently verified.
Positive control tissue: Adipose tissue (Adipocytes, HPA High)
Negative control tissue: None in HPA: NACC1 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead.
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show NACC1 in A-431, U-251MG, U2OS, MCF-7, PC-3, KOLF2.1J, with annotated localisation: Nucleoplasm (supported) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only slide and a control using rabbit IgG matched to the primary antibody’s isotype (caption: rabbit anti-NACC1 primary); use NACC1 knockout material or a validated peptide-blocking control for biological specificity. Quench endogenous peroxidase before chromogenic detection in adipose sections, and assess tissue autofluorescence if adapting the experiment to IF (standard IHC/IF practice).
⚠️Feasibility: The selected A08675-3 paraffin-section caption does not report a fixative, and no target-specific fixation window or fixation effect is reported in the supplied evidence (caption: fixative not stated). The caption uses heat retrieval in EDTA at pH 8.0, but does not establish that retrieval is required for NACC1 or that those conditions work in adipose tissue (caption: bladder carcinoma section, EDTA retrieval). Frozen sections and IF are not established as easier by the supplied evidence; for the proposed adipose positive control, monitor lipid-associated background and tissue autofluorescence when interpreting staining (standard IHC/IF practice).
HPA tissue IHC evidence for NACC1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — High consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | High | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | High | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | High | Protein (IHC) | HPA → |
| Caudate | Neuronal cells | High | Protein (IHC) | HPA → |
| Cerebral cortex | Glial cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| None in HPA: NACC1 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead. | ||||
Section 3
Advanced NACC1 IHC Tips
Troubleshoot NACC1 staining in paraffin sections by checking retrieval, nuclear localisation, detection background and how viable cells are scored.
How should I adjust retrieval when NACC1 nuclear staining is weak?
Start with heat-mediated antigen retrieval in EDTA at pH 8.0 for paraffin-section chromogenic IHC (datasheet A08675-3). The selected tissue image used that retrieval before overnight incubation at 4°C with 2 μg/ml primary antibody (caption A08675-3). If nuclear staining is weak, first check that sections received consistent heating and cooling, and compare them with a section processed in the same run (standard IHC practice). Only then consider a different retrieval buffer as a fallback, testing it alongside EDTA rather than treating it as a validated NACC1 condition (standard IHC practice). Judge improvement by nuclear signal and preserved tissue morphology (HPA: ubiquitous nuclear expression; standard IHC practice).
Could fixation explain weak or uneven NACC1 staining?
The selected paraffin-section image does not report its fixative, so NACC1-specific fixation sensitivity is unknown (caption A08675-3). Record fixative identity, fixation duration and processing history for each specimen before assigning a cause to weak staining (standard IHC practice). Compare sections processed together while keeping EDTA retrieval at pH 8.0 and the primary antibody concentration at 2 μg/ml (datasheet A08675-3; caption A08675-3). Change one processing variable at a time and inspect morphology as well as signal, because poorly preserved nuclei can make chromogenic scoring unreliable (standard IHC practice). Use a consistently processed comparison section to assess whether the problem tracks with the specimen or the staining run (standard IHC practice).
Should cytoplasmic NACC1 staining be considered nonspecific?
Expect a predominantly nuclear pattern in tissue: the tissue survey describes ubiquitous nuclear expression, while cell imaging supports nucleoplasmic localisation (HPA tissue IHC; HPA subcellular). Cytoplasmic signal is biologically plausible because NACC1 localisation there depends on phosphorylation, and cytosol is an additional reported location (UniProt Q96RE7 subcellular; HPA subcellular). NACC1 has no transmembrane segment, so a crisp membrane-only rim would warrant scrutiny rather than a membrane interpretation (UniProt Q96RE7 topology). Compare cytoplasmic and nuclear staining within the same intact cells, using matched chromogen development and a no-primary control to assess diffuse background (standard IHC practice). Report the two compartments separately when cytoplasmic staining persists across specimens (standard IHC practice).
What if retrieval reveals inconsistent NACC1 staining across specimens?
The supplied record lists 0 alternative isoforms, so an isoform switch is not an evidence-based explanation for discordant staining here (UniProt Q96RE7 isoforms). NACC1 contains a BTB domain at residues 30–94 and a BEN domain at 374–471, but the selected antibody’s epitope is not specified (UniProt Q96RE7 domains; caption A08675-3). Do not assume either domain is exposed or masked in a given paraffin section without epitope information (standard IHC practice). Hold EDTA at pH 8.0 constant while comparing staining runs, and document the tissue processing history before changing retrieval (datasheet A08675-3; standard IHC practice). If discordance persists, compare an independently validated epitope reagent with appropriate controls (standard IHC practice).
How can I assess NACC1 localisation by multiplex IF?
For a separate IF experiment, pair NACC1 with a marker identifying the cell population being assessed; an epithelial marker is relevant to the selected bladder epithelial carcinoma specimen (caption A08675-3; standard IF practice). Image a nuclear counterstain and the cell marker alongside NACC1 so nucleoplasmic signal can be assigned to individual cells (HPA subcellular; standard IF practice). Choose fluorophores after checking unstained tissue autofluorescence, favoring a spectrally separated far-red channel when shorter wavelengths are crowded (standard IF practice). Because NACC1 is intracellular and has no transmembrane segment, permeabilise fixed cells or sections to give antibody access to nuclear and cytosolic antigen (UniProt Q96RE7 topology and subcellular; standard IF practice). Establish IF fixation and permeabilisation conditions independently (standard IF practice).
How do I distinguish NACC1 signal from chromogenic background?
The selected paraffin-section method used 10% goat serum blocking, a biotinylated secondary, a streptavidin–biotin complex and DAB (caption A08675-3). Include a no-primary section to reveal detection-system staining, and block endogenous peroxidase before DAB development as part of the chromogenic workflow (standard IHC practice). If background follows endogenous biotin or enzyme-rich structures, assess the detection system with matched controls before changing the primary antibody (standard IHC practice). Widespread nuclear staining alone is not evidence of background because the tissue survey reports ubiquitous nuclear NACC1 expression (HPA tissue IHC). Compare intact nuclear detail with diffuse stromal or tissue-edge deposit under identical development conditions (standard IHC practice).
How should I score NACC1 staining across paraffin sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and region of interest before scoring, then assess nuclear DAB signal in viable, morphologically intact cells (standard IHC practice; HPA: ubiquitous nuclear expression). An H-score multiplies the percentage of cells at each intensity grade from 0–3 by that grade, yielding 0–300 (standard IHC practice). Record the percentage of positive cells as a companion measure, and score cytoplasmic staining separately if present because NACC1 can also localise there (standard IHC practice; UniProt Q96RE7 subcellular). Normalise counts or positive area to the number of eligible cells or viable tissue area, and apply the same threshold and DAB development criteria across cases (standard IHC practice).
When is strong NACC1 staining biologically credible rather than artefactual?
A credible tissue result has interpretable cellular morphology and predominantly nuclear staining, consistent with the reported tissue pattern and nucleoplasmic localisation (HPA tissue IHC; HPA subcellular). Verify which cells are positive: the selected image is from bladder epithelial carcinoma, while the tissue survey also reports NACC1 in several non-tumour cell populations (caption A08675-3; HPA tissue IHC). Be cautious with staining restricted to cut edges or necrotic areas, and use a no-primary control to investigate endogenous enzyme or detection-system deposits (standard IHC practice). Cytoplasmic staining can be plausible because NACC1 distribution there depends on phosphorylation, but a membrane-only pattern conflicts with its recorded topology (UniProt Q96RE7 subcellular and topology).
Boster reagents
Best NACC1 / Nucleus accumbens-associated protein 1 IHC Antibodies
A08675-3 has real IHC data from human paraffin sections and IF data from MCF-7 cells (catalog IHC and IF image captions).
Real IHC data
Anti-Nac1/NACC1 Antibody ®
Cat # A08675-3
A08675-3 is listed for human IHC, with images from paraffin sections of bladder epithelial carcinoma, breast papillary carcinoma, and renal pelvis squamous metaplasia (catalog applications, reactivity, and IHC image captions). The same SKU is listed for IF/ICC, with an IF image from MCF-7 cells (catalog applications and IF image caption).
Which to pick: For tissue IHC, choose A08675-3: its paraffin-section captions report EDTA retrieval at pH 8.0, 2 μg/ml primary antibody, and DAB detection; the fixative is unreported (catalog IHC image captions). For IF/ICC, A08675-3 is listed for both applications and has an MCF-7 IF image using 5 μg/ml primary antibody; its host is rabbit and clonality is unreported (catalog applications, IF image caption, host, and clone). No listed SKU has reported reactivity beyond human for cross-species selection (catalog: reactivity Human).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q96RE7 (NACC1_HUMAN, Nucleus accumbens-associated protein 1).
- Human Protein Atlas. NACC1 tissue IHC expression (reliability: Enhanced).
- Human Protein Atlas. NACC1 subcellular location (ICC-IF): Mainly localized to the nucleoplasm. In addition localized to vesicles and cytosol..
- Human Protein Atlas. NACC1 antibody validation summary (3 antibodies).
- NIPBL::NACC1 Fusion Hepatic Carcinoma. The American journal of surgical pathology 2024 — PMC11238093.
- NACC1, as a Target of MicroRNA-331-3p, Regulates Cell Proliferation in Urothelial Carcinoma Cells. Cancers 2018 — PMC6210667.
- Fatty acid synthase expression associated with NAC1 is a potential therapeutic target in ovarian clear cell carcinomas. British journal of cancer 2012 — PMC3394978.
- Loss of NAC1 expression is associated with defective bony patterning in the murine vertebral axis. PloS one 2013 — PMC3724875.
- PubMed PMID:15489334 — UniProt-cited evidence.
- PubMed PMID:17130457 — UniProt-cited evidence.
- PubMed PMID:17804717 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for NACC1 (Nucleus accumbens-associated protein 1). Expected localisation Nuclear tissue staining; cytoplasm is possible (HPA tissue IHC; UniProt). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A08675-3). Validated IHC antibody: A08675-3 at 2-5 μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Adipose tissue (Adipocytes); negative None in HPA (detected in all 45 tissues); use no-primary + isotype controls. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human bladder epithelial carcinoma tissue; fixative not specified (datasheet A08675-3); 2. Fixation: Image fixative and duration unreported (datasheet A08675-3); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A08675-3); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A08675-3); 8. Primary antibody: Rabbit anti-NACC1, 2-5 μg/ml (datasheet A08675-3); 9. Primary incubation: Overnight at 4 °C (datasheet A08675-3). Watch for: Fixation: Keep fixation conditions consistent across sections (standard IHC practice; not target-specific); Caveat: Phosphorylation may alter cytoplasmic distribution (UniProt); Isoform / epitope: No annotated isoforms; one full-length chain (UniProt); Regulation: Upregulated after chemotherapy in ovarian carcinoma (UniProt). Evidence: UniProt Q96RE7, HPA tissue IHC · Enhanced, HPA ICC-IF · Mainly localized to the nucleoplasm. In addition localized to…, Datasheet A08675-3, PMC6210667, PMC3724875. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/NACC1/immunohistochemistry-ihc-guide.